These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30906641)

  • 1. Combining peptide TNIIIA2 with all-
    Otsuka K; Sasada M; Iyoda T; Nohara Y; Sakai S; Asayama T; Suenaga Y; Yokoi S; Higami Y; Kodama H; Fukai F
    Am J Cancer Res; 2019; 9(2):434-448. PubMed ID: 30906641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation.
    Otsuka K; Sasada M; Hirano YU; Nohara Y; Iyoda T; Higami Y; Kodama H; Fukai F
    Anticancer Res; 2019 Jul; 39(7):3487-3492. PubMed ID: 31262872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: Combining peptide TNIIIA2 with all-
    Otsuka K; Sasada M; Iyoda T; Nohara Y; Sakai S; Asayama T; Suenaga Y; Yokoi S; Higami Y; Kodama H; Fukai F
    Am J Cancer Res; 2020; 10(1):365-366. PubMed ID: 32064173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of beta1 integrin induces proteasomal degradation of Myc oncoproteins.
    Sasada M; Iyoda T; Asayama T; Suenaga Y; Sakai S; Kase N; Kodama H; Yokoi S; Isohama Y; Fukai F
    Oncotarget; 2019 Aug; 10(48):4960-4972. PubMed ID: 31452837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.
    Duffy DJ; Krstic A; Halasz M; Schwarzl T; Konietzny A; Iljin K; Higgins DG; Kolch W
    Genome Med; 2017 Feb; 9(1):15. PubMed ID: 28187790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
    Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
    J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide.
    Reynolds CP; Wang Y; Melton LJ; Einhorn PA; Slamon DJ; Maurer BJ
    Med Pediatr Oncol; 2000 Dec; 35(6):597-602. PubMed ID: 11107126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
    Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
    J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells.
    Han G; Chang B; Connor MJ; Sidell N
    Differentiation; 1995 Jul; 59(1):61-9. PubMed ID: 7589896
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
    Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
    Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MYCN oncogene and differentiation in neuroblastoma.
    Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
    Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive auto-regulation of MYCN in human neuroblastoma.
    Suenaga Y; Kaneko Y; Matsumoto D; Hossain MS; Ozaki T; Nakagawara A
    Biochem Biophys Res Commun; 2009 Dec; 390(1):21-6. PubMed ID: 19766596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment.
    Edsjö A; Lavenius E; Nilsson H; Hoehner JC; Simonsson P; Culp LA; Martinsson T; Larsson C; Påhlman S
    Lab Invest; 2003 Jun; 83(6):813-23. PubMed ID: 12808116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.